The Journal of dermatological treatment最新文献_第8页

A year in review: new treatments and expanded indications in dermatology in 2024. 年度回顾：2024 年皮肤病学的新疗法和适应症扩展。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/09546634.2025.2456528

Lauren N McGrath, Lila G McGrath, John R Edminister

引用次数: 0

Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States. 美国患者和医疗保健提供者对脂溢性皮炎治疗模式和患者满意度的看法。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/09546634.2025.2476576

Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas

{"title":"Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.","authors":"Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas","doi":"10.1080/09546634.2025.2476576","DOIUrl":"10.1080/09546634.2025.2476576","url":null,"abstract":"Introduction: Seborrheic dermatitis (SD) affects a large, diverse population and is associated with significant morbidity/burden.Methods: The Harris Poll conducted online surveys to understand the perceptions, preferences, and experiences regarding treatments of US patients with SD and dermatology healthcare providers (HCPs) from December 2021 to January 2022.Results: In this survey, patients using SD treatment invested on average 34 min/d treating SD with 5.9 different treatments/week (cost: ∼$650/year). HCPs underestimated duration of SD treatment (16 min/d). Most patients agreed current treatment options are too time-consuming (61%), and would be more likely to continue a regimen with fewer treatments (88%). Few patients were 'very satisfied' with treatment option affordability (19%) and prescription treatment effectiveness (25%); only 8.7% of HCPs were satisfied with prescription SD treatment options available. Most patients acknowledged SD was difficult to treat (73%) and were interested in trying new treatments (87%). HCPs expressed the need for new treatments (92%) and agreed patients would be interested in trying them (95%). Patients prioritized symptom relief over look/feel of product and regimens that could be easily incorporated into hair routines. Patients would like HCPs to consider skin tone when recommending treatments (81%) and agreed cultural background affects treatment preference (55%).Conclusions: These findings suggest a need for SD treatments that address patient concerns/frustrations with current time-intensive complex regimens, and consider diverse hair care routines/cultural backgrounds.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2476576"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiolymphoid hyperplasia with eosinophilia responded well to dupilumab in two cases. 2例血管淋巴样增生伴嗜酸性粒细胞增多对dupilumab反应良好。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-14 DOI: 10.1080/09546634.2025.2485262

Yi Jiang, Yu Xiao, Yang Wang, Panpan Shang

{"title":"Angiolymphoid hyperplasia with eosinophilia responded well to dupilumab in two cases.","authors":"Yi Jiang, Yu Xiao, Yang Wang, Panpan Shang","doi":"10.1080/09546634.2025.2485262","DOIUrl":"https://doi.org/10.1080/09546634.2025.2485262","url":null,"abstract":"Purpose: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign vasoproliferative skin disorder. The overall efficacy of current treatments remains suboptimal with frequent recurrence. Recent studies have suggested the type-2 inflammation features of ALHE and emphasized the role of T cells, which calls for further validation.Material and methods: We describe two patients with ALHE, a 65-year-old man and a 27-year-old woman, treated with dupilumab, an IL-4 receptor α-antagonist that has been widely used in chronic skin diseases associated with type 2 inflammation.Results: Both patients achieved sustained responses to dupilumab with favorable safety profiles. The 65-year-old man showed significant improvement after 2 months of treatment, and discontinued treatment after 12 cycles. No relapse was observed during a 3-month follow-up. The 27-year-old woman showed reduced nodules on the forehead after 4 cycles of treatment and continued the treatment at 300 mg per month for 7 months without relapse.Conclusions: These cases support the type 2 inflammation features of ALHE and underscore the critical role of T cells in the pathogenesis. Moreover, these cases also highlight the promising use of dupilumab or other T-helper cell type 2-mediating therapies in treating ALHE.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2485262"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis. 吡美莫司乳膏1%治疗可改善皮质类固醇引起的皮肤损伤：一项针对轻度至中度特应性皮炎成人的1年研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-20 DOI: 10.1080/09546634.2025.2493931

Diamant Thaçi, Matthias Bräutigam, Thomas Luger

{"title":"Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis.","authors":"Diamant Thaçi, Matthias Bräutigam, Thomas Luger","doi":"10.1080/09546634.2025.2493931","DOIUrl":"10.1080/09546634.2025.2493931","url":null,"abstract":"Background and objectives: Long-term treatment with topical corticosteroids (TCS) can lead to skin atrophy and telangiectasia at the application site. The objective of this study was to investigate if reversal of TCS-induced skin damage in patients with atopic dermatitis (AD) can be achieved by treatment with pimecrolimus cream 1%, especially in sensitive skin areas like the face.Methods: Forty-one adult patients with mild to moderate atopic dermatitis and preexisting moderate TCS-induced skin damage on the face and cubital areas were intermittently treated for 48-52 weeks with pimecrolimus cream 1%. Skin atrophy and telangiectasia were evaluated by a dermatoscope connected to a digital camera (Dermatophot). In 11 patients skin thickness was measured by ultrasound.Results: Compared with baseline, the Dermatophot score improved by 30.5% (p < .0001; 95% CI: 20.8%-40.1%) on the face and by 38.6% (p < .0001; 95% CI: 28.2%-49.0%) on the cubital areas. In parallel, skin thickness increased by 64.4% (p = .002) on the face and by 19.9% (p = .016) on the cubital areas. During the study clinical symptoms improved in almost 60% of the patients.Conclusion: Reversal of TCS-induced skin atrophy/telangiectasia was observed in approximately 1/2 of patients using chronic intermittent treatment with pimecrolimus cream 1%.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2493931"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. 白癜风患者的抑郁和抑郁症状：来自横断面、基于人群的全球VALIANT调查的结果

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2504082

Khaled Ezzedine, Davinder Parsad, John E Harris, Nanja van Geel, Jackie Gardner, Kristen Bibeau, Jessy Gao, Haobo Ren, Iltefat H Hamzavi

{"title":"Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey.","authors":"Khaled Ezzedine, Davinder Parsad, John E Harris, Nanja van Geel, Jackie Gardner, Kristen Bibeau, Jessy Gao, Haobo Ren, Iltefat H Hamzavi","doi":"10.1080/09546634.2025.2504082","DOIUrl":"https://doi.org/10.1080/09546634.2025.2504082","url":null,"abstract":"Purpose: Vitiligo often affects quality of life and psychosocial well-being. This analysis of the population-based global Vitiligo and Life Impact Among International Communities (VALIANT) study sought to understand the impact of vitiligo on depression and depressive symptoms from the patient perspective.Materials and methods: The cross-sectional survey collected information on patient demographics, clinical characteristics, mental health diagnoses, and depressive symptoms (assessed using the Patient Health Questionnaire-Depression screener [PHQ-9]) among recruited patients who reported a vitiligo diagnosis.Results: Of 3541 VALIANT respondents, 24.5% reported formal diagnosis of depression, and 55.0% reported moderate-to-severe symptoms of depression per the PHQ-9. Rates of formally diagnosed depression and moderate-to-severe depressive symptoms were significantly higher in younger patients, those with Fitzpatrick skin types IV-VI (i.e. darker skin), >5% affected body surface area, hand or face involvement, and those receiving mental healthcare versus their counterparts (all p < 0.0001). Interestingly, moderate-to-severe depressive symptoms were more common among patients with shorter disease duration (≤2 vs 3-9 and ≥10 years; p < 0.01), but there was no correlation between diagnosed depression and disease duration.Conclusions: These VALIANT study findings highlight that depression may be common but often undiagnosed among patients with vitiligo, reinforcing the importance of an improved and multifaceted approach to vitiligo management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2504082"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis. 米诺地尔单独与米诺地尔联合低水平激光治疗雄激素性脱发的疗效比较：一项系统回顾和荟萃分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2024.2447355

Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi

{"title":"Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis.","authors":"Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi","doi":"10.1080/09546634.2024.2447355","DOIUrl":"10.1080/09546634.2024.2447355","url":null,"abstract":"Objective: This systematic review evaluates the efficacy of minoxidil alone versus minoxidil with low-level laser therapy (LLLT) for androgenic alopecia.Study design: systematic review and meta-analysis.Methods: An online search of PubMed, Web of Science, and MEDLINE was conducted. Randomized clinical trials comparing minoxidil monotherapy with minoxidil and LLLT combination therapy were included based on predefined criteria. The Risk of Bias 2.0 (RoB 2.0) tool was used for quality assessment.Results: From 38 identified studies, 34 remained after excluding 4 duplicates. Further exclusions left 4 eligible studies comparing minoxidil alone with minoxidil and LLLT. The meta-analysis found no statistically significant differences in hair counts between the two groups at baseline, 12 weeks, and 8 weeks post-treatment [mean difference = -0.04, 95% CI -1.22 to 1.14, p = .95, I² = 0%]. Similarly, hair diameter showed no significant differences at the same time points [mean difference = 0.00, 95% CI -0.00 to 0.00, p = .98, I² = 38%].Conclusion: The combination of minoxidil and LLLT does not significantly improve outcomes compared to minoxidil alone for treating androgenic alopecia.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447355"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis. 儿童特应性皮炎患者的转诊、评估和管理模式在变态反应学和皮肤科的差异。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-09 DOI: 10.1080/09546634.2025.2515495

Nicole L Edmonds, Courtney E Heron, Monica G Lawrence, Barrett Zlotoff

{"title":"Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis.","authors":"Nicole L Edmonds, Courtney E Heron, Monica G Lawrence, Barrett Zlotoff","doi":"10.1080/09546634.2025.2515495","DOIUrl":"https://doi.org/10.1080/09546634.2025.2515495","url":null,"abstract":"Introduction: Allergists and dermatologists often take different approaches to caring for pediatric patients with atopic dermatitis (AD).Methods: A retrospective chart review was performed on patients <18 years old treated for AD within the University of Virginia health system from 2015 to 2020. Data were collected on patient and referring provider demographics as well as initial visit evaluation and management.Results: A total of 269 patients presented to allergy, 685 patients presented to dermatology, and 14 patients presented to a combined allergy-dermatology clinic as an initial visit with a primary diagnosis of AD. Both specialties were most often referred to by a generalist though dermatology received more specialty provider referrals. In addition, allergy ordered more diagnostic testing (IgE, allergens, complete blood count), while dermatology prescribed more medications (topical corticosteroids, topical calcineurin inhibitors, immunosuppressants). Patients seen in the combined dermatology-allergy clinic were more likely to receive diagnostic testing than patients seen in dermatology clinic and were more likely to be prescribed medications than patients seen in allergy clinic.Conclusions: Our findings suggest allergists may focus more on identifying triggers of AD, while dermatologists largely focus on the prescription of therapies. Clinical care may be more comprehensive when allergists and dermatologists work synergistically.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2515495"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of quality of life and economic burden in patients with chronic urticaria: a comparative study of spontaneous and induced urticaria and its effects on cognition of biologics. 慢性荨麻疹患者的生活质量和经济负担分析：自发性和诱发性荨麻疹的比较研究及其对生物制剂认知的影响。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/09546634.2025.2506672

Shixi Ma, Zixuan Wang, Yaxin Zhang, Guan Jiang

{"title":"Analysis of quality of life and economic burden in patients with chronic urticaria: a comparative study of spontaneous and induced urticaria and its effects on cognition of biologics.","authors":"Shixi Ma, Zixuan Wang, Yaxin Zhang, Guan Jiang","doi":"10.1080/09546634.2025.2506672","DOIUrl":"10.1080/09546634.2025.2506672","url":null,"abstract":"Objective: To compare and analyze the quality of life, economic burden, and knowledge about biological agents between chronic spontaneous urticaria (CSU) and chronic induced urticaria (ClndU), and to provide a reference for clinical rational drug use and patient classification management.Methods: This cross-sectional multicenter study involved 386 chronic urticaria (CU) patients from three hospitals in various regions, seen between November 2024 and April 2025. Data on demographics, clinical characteristics, Dermatological Quality of Life Index (DLQI), economic burden, and knowledge about biological agents were collected.Results: 228 CSU patients and 158 CIndU patients. CSU patients had higher DLQI score than CIndU patients (p < .05). CU type, comorbidities, and urticaria control test score were identified as factors affecting the quality of life of CU patients. CSU patients had higher outpatient costs compared to CIndU patients (p < .05). CU type, insurance type, comorbidities, and disease duration were factors influencing outpatient costs. CSU patients exhibited better understanding of relapse and complete remission compared to CIndU patients (p < .05).Conclusion: Notable differences exist between CSU and CIndU patients in terms of quality of life, economic impact, and knowledge about biological agents. Therefore, it is necessary to categorize these patients to enhance their understanding and utilization of biological agents.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2506672"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 使用upadacitinib治疗中重度特应性皮炎：患者分析，剂量选择和治疗调节，现实生活教给我们什么？

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-09 DOI: 10.1080/09546634.2025.2509541

Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo

{"title":"Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?","authors":"Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo","doi":"10.1080/09546634.2025.2509541","DOIUrl":"10.1080/09546634.2025.2509541","url":null,"abstract":"Purpose: This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods: A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monotherapy. Clinical outcomes were evaluated up to 104 weeks using Eczema Area and Severity Index (EASI), itch and sleep numeric rating scale (NRS), and Dermatology Life Quality Index (DLQI).Results: Both dosages led to significant and sustained improvements in disease severity, pruritus, sleep disturbances, and quality of life, with 77.8% achieving EASI 75 and 39.2% achieving EASI 100 at week 16. Responses were similar between doses, although long-term itch control was better in the 30 mg group. Higher baseline EASI score was a positive predictor of response, while head and neck involvement and prior systemic treatments, particularly cyclosporine, were associated with poorer outcomes. The safety profile was consistent with prior reports, with acneiform eruption, elevated creatine phosphokinase (CPK), and dyslipidemia being the most common adverse events. No reactivation of atopic keratoconjunctivitis was observed.Conclusions: These findings support the efficacy, safety, and flexibility of upadacitinib dosing in clinical practice.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2509541"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of skin flap transfer combined with negative pressure wound therapy in the management of complex pressure ulcers. 皮瓣转移联合负压创面治疗复杂压疮的疗效观察。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-28 DOI: 10.1080/09546634.2025.2537752

Jing Wen, Xinxin Hu

引用次数: 0